
In another embodiment~~aspect~~, the application provides a compound of formula I



I

or a pharmaceutically acceptable salt thereof,

wherein:

Y' is CH or N;

X is CH or N;

each X^1 is independently halogen, lower alkyl, lower alkoxy, lower haloalkyl, or hydroxy;

m is 0, 1, or 2;

X^2 is H, lower alkyl, lower alkoxy, amido, lower haloalkyl, or lower haloalkoxy;

X^3 is lower alkyl, lower alkoxy, or lower haloalkyl;

p is 0 or 1;

each X^4 is independently lower alkyl, lower alkoxy, lower haloalkyl, hydroxy, lower hydroxylalkyl, $OC(=O)Z^2$, or halogen;

q is 0, 1, or 2;

s is 0;

r is 0 or 1;

Y is H, OH, $C(=O)Z^2$, $C(=O)OZ^2$, OZ^2, $OC(=O)Z^2$, $N(Z^1)C(=O)(Z^2)$, $C(Z^1)_2S(O)_2Z^2$, $N(Z^1)S(O)_2Z^2$, $N(Z^1)S(O)_2N(Z^1)(Z^2)$, $C(Z^1)_2(Z^2)$, or $(C=O)N(Z^1)(Z^2)$;

Z^1 is H or $Z^{1'}$;

$Z^{1'}$ is lower alkyl, optionally substituted with one or more $Z^{1''}$;

each $Z^{1''}$ is independently halogen, hydroxy, lower haloalkyl, or amino;

Z^2 is H or $Z^{2'}$;

$Z^{2'}$ is lower alkyl, lower alkoxy, lower hydroxyalkyl, lower haloalkyl, cycloalkyl, cycloalkyl lower alkyl, heterocycloalkyl, heterocycloalkyl lower alkyl, optionally substituted with one or more $Z^{2''}$;

each $Z^{2''}$ is independently halogen, hydroxy, lower alkyl, cyano, lower haloalkyl, amino, carboxylic acid, ester, or lower alkoxy;

R^1 is C(=O), C(=O)O, $C(=O)CH_2OC(=O)$, $C(=O)CH_2NHC(=O)O$, or $S(=O)_2$;

R^2 is H or $R^{2'}$;


$R^{2'}$ is lower alkyl, $N(R^3)_2$, lower hydroxyalkyl, or lower haloalkyl, optionally substituted with one or more $R^{2''}$;

each $R^{2''}$ is independently cyano, amino, hydroxy, lower hydroxyalkyl, or lower alkoxy; and

each R^3 is independently H, lower alkyl, lower cycloalkyl, phenyl, lower heterocycloalkyl, or both R^3 together form a heterocyclic ring;

with the proviso that when X is N, X^2 is H, Y' is CH, R^1 is C(=O), R^2 is methyl, r is 1, m is 0, p is 0, q is 0, Y is $N(Z^1)S(O)_2Z^2$, and Z^2 is methyl, then Z^1 is not H or hydroxyethyl.

In a further embodiment~~aspect~~, the application provides a compound of formula I



I

or a pharmaceutically acceptable salt thereof,

wherein:

Y' is CH or N;

X is CH or N;

m is 0;

X^2 is H or amido;

p is 0

each X^4 is independently lower alkyl, hydroxy, $OC(=O)Z^2$;

q is 0 or 1;

X^5 is lower alkyl;

In one variation of formula I, m is 0, p is 0, q is 0, r is 1, X is CH, Y' is CH, R^1 is $S(=O)_2$, R^2 is $R^{2'}$, and $R^{2'}$ is methyl.

In one variation of formula I, R^1 is C(=O), R^2 is $R^{2'}$, $R^{2'}$ is methylene, and $R^{2''}$ is cyano.

In one variation of formula I, R^1 is $S(=O)_2$, R^2 is $R^{2'}$, and $R^{2'}$ is methyl.

In one variation of formula I, wherein Y' is N.

In one variation of formula I, m is 0, X^2 is H, p is 0, q is 0, r is 1, X is CH, Y' is N, R^1 is $S(=O)_2$, R^2 is $R^{2'}$, and $R^{2'}$ is methyl.

In certain embodiment of formula I, Y is OH.

The application, in a second aspect, provides the compounds of Formula I selected from the group consisting of:

N-{4-[4-(4-Piperazin-1-yl-indol-1-yl)-pyrimidin-2-ylamino]-cyclohexyl}-methanesulfonamide;

4-[4-(4-Piperidin-1-yl-indol-1-yl)-pyrimidin-2-ylamino]-cyclohexanol;

N-(4-{4-[4-(4-Methanesulfonyl-piperazin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-methanesulfonamide;

N-(4-{4-[4-(4-Hydroxy-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-methanesulfonamide;

N-(4-{4-[4-(4-Acetyl-piperazin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-*N*-methyl-methanesulfonamide;

N-(4-{4-[4-(4-Methanesulfonyl-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-methanesulfonamide;

4-{1-[2-(4-Methanesulfonylamino-cyclohexylamino)-pyrimidin-4-yl]-1*H*-indol-4-yl}-piperazine-1-carboxylic acid amide;

4-{1-[2-(4-Methanesulfonylamino-cyclohexylamino)-pyrimidin-4-yl]-1*H*-indol-4-yl}-piperazine-1-sulfonic acid amide;

N-[4-(4-{4-[4-(2-Cyano-acetyl)-piperazin-1-yl]-indol-1-yl}-pyrimidin-2-ylamino)-cyclohexyl]-methanesulfonamide;

3-(4-{1-[2-((1S,3R)-3-Hydroxy-cyclopentylamino)-pyrimidin-4-yl]-1*H*-indol-4-yl}-piperazin-1-yl)-3-oxo-propionitrile;

3-(4-{1-[2-((1R,3S)-3-Hydroxy-cyclopentylamino)-pyrimidin-4-yl]-1*H*-indol-4-yl}-piperazin-1-yl)-3-oxo-propionitrile;

3-(4-{1-[2-((1S,3S)-3-Hydroxy-cyclopentylamino)-pyrimidin-4-yl]-1*H*-indol-4-yl}-piperazin-1-yl)-3-oxo-propionitrile;

3-(4-{1-[2-((1R,3R)-3-Hydroxy-cyclopentylamino)-pyrimidin-4-yl]-1*H*-indol-4-yl}-piperazin-1-yl)-3-oxo-propionitrile;

4-{4-[4-(4-Methanesulfonyl-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexanol;

4-(4-Acetyl-piperazin-1-yl)-1-[2-(4-hydroxy-cyclohexylamino)-pyrimidin-4-yl]-1*H*-indole-3-carboxylic acid amide;

4-(4-Acetyl-piperazin-1-yl)-1-[2-(4-methanesulfonylmethyl-cyclohexylamino)-pyrimidin-4-yl]-1*H*-indole-3-carboxylic acid amide;

4-{4-[4-(4-Methanesulfonyl-piperidin-1-yl)-indazol-1-yl]-pyrimidin-2-ylamino}-cyclohexanecarboxylic acid ethyl ester; and

4-{4-[4-(4-Methanesulfonyl-piperidin-1-yl)-indazol-1-yl]-pyrimidin-2-ylamino}-cyclohexanol.

In one embodimentaspect, the application provides a method of treating a JNK-mediated disorder in a subject having a JNK-mediated disorder, said method comprising administering to a subject in need thereof a therapeutically effective amount of any of the above compounds.

In certain embodiments of the method of treating a JNK-mediated disorder, the JNK-mediated disorder is characterized by cellular proliferation.

In certain embodiments of the method of treating a JNK-mediated disorder, the JNK-mediated disorder is arthritis.

In certain embodiments of the method of treating a JNK-mediated disorder, the arthritis is rheumatoid arthritis.

In certain embodiments of the method of treating a JNK-mediated disorder, the JNK-mediated disorder is asthma.

In certain embodiments of the method of treating a JNK-mediated disorder, the JNK-mediated disorder is diabetes.

In certain embodiments of the method of treating a JNK-mediated disorder, the JNK-mediated disorder is Alzheimer's disease.

In certain embodiments of the method of treating a JNK-mediated disorder, the JNK-mediated disorder is Parkinson's disease.

In certain embodiments of the method of treating a JNK-mediated disorder, the JNK-mediated disorder is ischemic stroke.

In certain embodiments of the method of treating a JNK-mediated disorder, the JNK-mediated disorder is cancer.

In certain embodiments of the method for treating a JNK-mediated disorder, wherein the JNK-mediated disorder is cancer, the cancer is brain cancer.

In certain embodiments of the method for treating a JNK-mediated disorder, wherein the JNK-mediated disorder is cancer, the cancer is leukemia.

In certain embodiments of the method of treating a JNK-mediated disorder, the JNK-mediated disorder is kidney disease.

In one embodiment~~aspect~~, the application provides a pharmaceutical composition comprising the compound of any one of the above embodiments, admixed with at least one pharmaceutically acceptable carrier, excipient or diluent.

A method for treating arthritis comprising co-administering to a patient in need thereof a therapeutically effective amount of an anti-inflammatory compound in combination with the compound of any of the above embodiments, variations, or aspects.

In a further embodiment~~aspect~~, the application provides the use of any of the above compounds for the preparation of medicaments for the therapeutic and/or prophylactic treatment of a JNK mediated disorder.

In certain embodiments of the use of the above compound for the preparation of medicament wherein JNK mediated disorder is autoimmune disorder, inflammatory disorder, metabolic disorder, neurological disease, or cancer

In certain embodiments of the use of the above compound for the preparation of medicament wherein JNK mediated disorder is rheumatoid arthritis, asthma, type II diabetes, Alzheimer's disease, Parkinson's disease or stroke.

In a further embodiment~~aspect~~, the application provides the compound of any of the above embodiments for use in the treatment of a JNK mediated disorder.

All publications cited in this disclosure are incorporated herein by reference in their entirety.


Definitions

Unless otherwise stated, the following terms used in this Application, including the specification and claims, have the definitions given below. It must be noted that, as used in the specification and the appended claims, the singular forms "a", "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, the phrase ""a" or "an" entity' as used herein refers to one or more of that entity; for example, a compound refers to one or more compounds or at least one compound. As such, the terms "a" (or "an"), "one or more", and "at least one" can be used interchangeably herein.

As used in this specification, whether in a transitional phrase or in the body of the claim, the terms "comprise(s)" and "comprising" are to be interpreted as having an open-ended meaning. That is, the terms are to be interpreted synonymously with the phrases "having at least" or "including at least". When used in the context of a process, the term "comprising" means that the process includes at least the recited steps, but may include additional steps. When used in the context of a compound or composition, the term "comprising" means that the compound

Claims:

1. A compound of formula **I**



I

or a pharmaceutically acceptable salt thereof,

wherein:

Y' is CH or N;

X is CH or N;

each X^1 is independently halogen, lower alkyl, lower alkoxy, lower haloalkyl, or hydroxy;

m is 0, 1, or 2;

X^2 is H, lower alkyl, lower alkoxy, amido, lower haloalkyl, or lower haloalkoxy;

X^3 is lower alkyl, lower alkoxy, or lower haloalkyl;

p is 0 or 1;

each X^4 is independently lower alkyl, lower alkoxy, lower haloalkyl, hydroxy, lower hydroxylalkyl, $OC(=O)Z^2$, or halogen;

q is 0, 1, or 2;

X^5 is lower alkyl;

s is 0, 1 or2;

r is 0 or 1;

Y is H, OH, $C(=O)Z^2$, $C(=O)OZ^2$, OZ^2, $OC(=O)Z^2$, $N(Z^1)C(=O)(Z^2)$, $C(Z^1)_2S(O)_2Z^2$, $N(Z^1)S(O)_2Z^2$, $N(Z^1)S(O)_2N(Z^1)(Z^2)$, $C(Z^1)_2(Z^2)$, or $(C=O)N(Z^1)(Z^2)$;

Z^1 is H or $Z^{1'}$;

$Z^{1'}$ is lower alkyl, optionally substituted with one or more $Z^{1''}$;

each $Z^{1''}$ is independently halogen, hydroxy, lower haloalkyl, dialkylamino or amino;

Z^2 is H or $Z^{2'}$;

$Z^{2'}$ is hydroxy, lower alkyl, lower alkoxy, lower hydroxyalkyl, lower haloalkyl, cycloalkyl, cycloalkyl lower alkyl, heterocycloalkyl, heterocycloalkyl lower alkyl, optionally substituted with one or more $Z^{2''}$;

each $Z^{2''}$ is independently halogen, hydroxy, lower alkyl, cycloalkyl, cyano, lower haloalkyl, amino, carboxylic acid, ester, or lower alkoxy;

R^1 is a bond, C(=O), C(=O)O, $C(=O)CH_2OC(=O)$, $C(=O)CH_2NHC(=O)O$, or $S(=O)_2$;

R^2 is H or $R^{2'}$;

$R^{2'}$ is hydroxy, lower alkyl, $N(R^3)_2$, lower hydroxyalkyl, or lower haloalkyl, optionally substituted with one or more $R^{2''}$;

each $R^{2''}$ is independently cyano, amino, dialkylamino, hydroxy, lower hydroxyalkyl, or lower alkoxy; and

each R^3 is independently H, lower alkyl, lower cycloalkyl, phenyl, lower heterocycloalkyl, or both R^3 together form a heterocyclic ring;

with the proviso that when X is N, X^2 is H, Y' is CH, R^1 is C(=O), R^2 is methyl, r is 1, m is 0, p is 0, q is 0, Y is $N(Z^1)S(O)_2Z^2$, and Z^2 is methyl, then Z^1 is not H or hydroxyethyl.

2. The compound according to claim 1 wherein:

Y' is CH or N;

X is CH or N;

each X^1 is independently halogen, lower alkyl, lower alkoxy, lower haloalkyl, or hydroxy;

m is 0, 1, or 2;

X^2 is H, lower alkyl, lower alkoxy, amido, lower haloalkyl, or lower haloalkoxy;

X^3 is lower alkyl, lower alkoxy, or lower haloalkyl;

p is 0 or 1;

each X^4 is independently lower alkyl, lower alkoxy, lower haloalkyl, hydroxy, lower hydroxylalkyl, $OC(=O)Z^2$, or halogen;

q is 0, 1, or 2;

s is 0;

r is 0 or 1;

Y is H, OH, $C(=O)Z^2$, $C(=O)OZ^2$, OZ^2, $OC(=O)Z^2$, $N(Z^1)C(=O)(Z^2)$, $C(Z^1)_2S(O)_2Z^2$, $N(Z^1)S(O)_2Z^2$, $N(Z^1)S(O)_2N(Z^1)(Z^2)$, $C(Z^1)_2(Z^2)$, or $(C=O)N(Z^1)(Z^2)$;

Z^1 is H or $Z^{1'}$;

$Z^{1'}$ is lower alkyl, optionally substituted with one or more $Z^{1''}$;

each $Z^{1''}$ is independently halogen, hydroxy, lower haloalkyl, or amino;

Z^2 is H or $Z^{2'}$;

$Z^{2'}$ is lower alkyl, lower alkoxy, lower hydroxyalkyl, lower haloalkyl, cycloalkyl, cycloalkyl lower alkyl, heterocycloalkyl, heterocycloalkyl lower alkyl, optionally substituted with one or more $Z^{2''}$;

each $Z^{2''}$ is independently halogen, hydroxy, lower alkyl, cyano, lower haloalkyl, amino, carboxylic acid, ester, or lower alkoxy;

R^1 is C(=O), C(=O)O, $C(=O)CH_2OC(=O)$, $C(=O)CH_2NHC(=O)O$, or $S(=O)_2$;

R^2 is H or $R^{2'}$;

$R^{2'}$ is lower alkyl, $N(R^3)_2$, lower hydroxyalkyl, or lower haloalkyl, optionally substituted with one or more $R^{2''}$;

each $R^{2''}$ is independently cyano, amino, hydroxy, lower hydroxyalkyl, or lower alkoxy; and

each R^3 is independently H, lower alkyl, lower cycloalkyl, phenyl, lower heterocycloalkyl, or both R^3 together form a heterocyclic ring;

with the proviso that when X is N, X^2 is H, Y' is CH, R^1 is C(=O), R^2 is methyl, r is 1, m is 0, p is 0, q is 0, Y is $N(Z^1)S(O)_2Z^2$, and Z^2 is methyl, then Z^1 is not H or hydroxyethyl.

3. The compound according to either claim 1 or 2 wherein:

Y' is CH or N;

X is CH or N;

m is 0;

X^2 is H or amido;

p is 0

each X^4 is independently lower alkyl, hydroxy, $OC(=O)Z^2$;

q is 0 or 1;

s is 0 ;

r is 0 or 1;

Y is H, OH, $C(=O)Z^2$, $C(=O)OZ^2$, OZ^2, $N(Z^1)C(=O)(Z^2)$, $C(Z^1)_2S(O)_2Z^2$, $N(Z^1)S(O)_2Z^2$, $N(Z^1)S(O)_2N(Z^1)(Z^2)$, $C(Z^1)_2(Z^2)$, or $(C=O)N(Z^1)(Z^2)$;

Z^1 is H or $Z^{1'}$;

$Z^{1'}$ is lower alkyl, optionally substituted with one or more $Z^{1''}$;

each $Z^{1''}$ is dialkylamino;

Z^2 is H or $Z^{2'}$;

$Z^{2'}$ is hydroxy, lower alkyl or heterocycloalkyl, optionally substituted with one or more $Z^{2''}$;

each $Z^{2''}$ is independently hydroxy, lower alkyl, cycloalkyl, cyano, or lower alkoxy;

R^1 is a bond, C(=O), $C(=O)CH_2OC(=O)$, $C(=O)CH_2NHC(=O)O$, or $S(=O)_2$;

R^2 is H or $R^{2'}$;

$R^{2'}$ is hydroxy, lower alkyl, $N(R^3)_2$, lower hydroxyalkyl, optionally substituted with one or more $R^{2''}$;

each $R^{2''}$ is independently cyano, amino or dialkylamino; and

each R^3 is H ;

with the proviso that when X is N, X^2 is H, Y' is CH, R^1 is C(=O), R^2 is methyl, r is 1, m is 0, p is 0, q is 0, Y is $N(Z^1)S(O)_2Z^2$, and Z^2 is methyl, then Z^1 is not H.

4. The compound according to any one of claims 1 to 3, wherein m is 0, X^2 is H, p is 0, q is 0, r is 0, X is N, Y' is CH, R^1 is C(=O), R^2 is $R^{2'}$, $R^{2'}$ is methylene, and $R^{2''}$ is cyano.

5. The compound according to any one of claims 1 to 4, wherein m is 0, p is 0, q is 0, r is 1, X is N, Y' is CH, R^1 is C(=O), R^2 is $R^{2'}$, $R^{2'}$ is methylene, and $R^{2''}$ is cyano.

6. The compound according to any one of claims 1 to 5, wherein m is 0, X^2 is H, p is 0, q is 0, r is 1, X is N, Y' is CH, R^1 is C(=O), R^2 is $R^{2'}$, and $R^{2'}$ is methyl.

7. The compound according to any one of claims 1 to 6, wherein m is 0, p is 0, q is 0, r is 1, X is CH, Y' is CH, R^1 is $S(=O)_2$, R^2 is $R^{2'}$, and $R^{2'}$ is methyl.

8. The compound according to any one of claims 1 to 7, wherein R^1 is C(=O), R^2 is $R^{2'}$, $R^{2'}$ is methylene, and $R^{2''}$ is cyano.

9. The compound according to any one of claims1 to 8, wherein R^1 is $S(=O)_2$, R^2 is $R^{2'}$, and $R^{2'}$ is methyl.

10. The compound according to any one of claims 1 to 3, wherein Y' is N.

11. The compound according to any one of claims 1 to 3, m is 0, X^2 is H, p is 0, q is 0, r is 1, X is CH, Y' is N, R^1 is $S(=O)_2$, R^2 is $R^{2'}$, and $R^{2'}$ is methyl.

12. The compound according to any one of claims 1 to 11, wherein s is 0.

13. A compound selected from the group consisting of:

N-{4-[4-(4-Piperazin-1-yl-indol-1-yl)-pyrimidin-2-ylamino]-cyclohexyl}-methanesulfonamide;

4-[4-(4-Piperidin-1-yl-indol-1-yl)-pyrimidin-2-ylamino]-cyclohexanol;

N-(4-{4-[4-(4-Methanesulfonyl-piperazin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-methanesulfonamide;

N-(4-{4-[4-(4-Hydroxy-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-methanesulfonamide;

N-(4-{4-[4-(4-Acetyl-piperazin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-*N*-methyl-methanesulfonamide;

N-(4-{4-[4-(4-Methanesulfonyl-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-methanesulfonamide;

4-{1-[2-(4-Methanesulfonylamino-cyclohexylamino)-pyrimidin-4-yl]-1*H*-indol-4-yl}-piperazine-1-carboxylic acid amide;

4-{1-[2-(4-Methanesulfonylamino-cyclohexylamino)-pyrimidin-4-yl]-1*H*-indol-4-yl}-piperazine-1-sulfonic acid amide;

N-[4-(4-{4-[4-(2-Cyano-acetyl)-piperazin-1-yl]-indol-1-yl}-pyrimidin-2-ylamino)-cyclohexyl]-methanesulfonamide;

Acetic acid 2-(4-{1-[2-(4-methanesulfonylamino-cyclohexylamino)-pyrimidin-4-yl]-1*H*-indol-4-yl}-piperazin-1-yl)-2-oxo-ethyl ester;

N-[4-(4-{4-[4-(2-Hydroxy-acetyl)-piperazin-1-yl]-indol-1-yl}-pyrimidin-2-ylamino)-cyclohexyl]-methanesulfonamide;

4-{4-[4-(4-Methanesulfonyl-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexanol;

N-(4-{4-[4-(4-Methanesulfonyl-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-acetamide;

2-(4-{4-[4-(4-Methanesulfonyl-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-propan-2-ol;

[4-{4-[4-(4-Methanesulfonyl-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl] aminodimethylsulfonamide;

4-{4-[4-(4-Methanesulfonyl-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-1-methyl-cyclohexanol;

4-{4-[4-(4-Methanesulfonyl-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-1-methyl-cyclohexanol;

(4-Hydroxy-piperidin-1-yl)-(4-{4-[4-(4-methanesulfonyl-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-methanone;

4-{4-[4-(4-Methanesulfonyl-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexanecarboxylic acid ethylamide;

4-{4-[4-(4-Methanesulfonyl-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexanecarboxylic acid ethyl ester;

1-[(R)-4-(1-{2-[4-(4-Hydroxy-piperidine-1-carbonyl)-cyclohexylamino]-pyrimidin-4-yl}-1*H*-indol-4-yl)-3-methyl-piperazin-1-yl]-ethanone;

[2-(4-{1-[2-(4-Methanesulfonylamino-cyclohexylamino)-pyrimidin-4-yl]-1*H*-indol-4-yl}-piperazin-1-yl)-2-oxo-ethyl]-carbamic acid *tert*-butyl ester;

N-[4-(4-{4-[4-(2-Dimethylamino-acetyl)-piperazin-1-yl]-indol-1-yl}-pyrimidin-2-ylamino)-cyclohexyl]-methanesulfonamide;

N-[4-(4-{4-[4-(2-Amino-acetyl)-piperazin-1-yl]-indol-1-yl}-pyrimidin-2-ylamino)-cyclohexyl]-methanesulfonamide;

3-[4-(1-{2-[4-((R)-3-Hydroxy-pyrrolidin-1-ylmethyl)-cyclohexylamino]-pyrimidin-4-yl}-1*H*-indol-4-yl)-piperazin-1-yl]-3-oxo-propionitrile;

N-[4-(4-{4-[4-(2-Cyano-acetyl)-piperazin-1-yl]-indol-1-yl}-pyrimidin-2-ylamino)-cyclohexyl]-*N*-(2-dimethylamino-ethyl)-methanesulfonamide;

3-(4-{1-[2-(4-Hydroxymethyl-cyclohexylamino)-pyrimidin-4-yl]-1*H*-indol-4-yl}-piperazin-1-yl)-3-oxo-propionitrile;

3-[4-(1-{2-[4-((S)-3-Hydroxy-pyrrolidin-1-ylmethyl)-cyclohexylamino]-pyrimidin-4-yl}-1*H*-indol-4-yl)-piperazin-1-yl]-3-oxo-propionitrile;

1-[4-(1-{2-[4-((R)-3-Hydroxy-pyrrolidin-1-ylmethyl)-cyclohexylamino]-pyrimidin-4-yl}-1*H*-indol-4-yl)-piperazin-1-yl]-ethanone;

(4-Ethoxy-piperidin-1-yl)-(4-{4-[4-(4-methanesulfonyl-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-methanone;

((R)-3-Ethoxy-pyrrolidin-1-yl)-(4-{4-[4-(4-methanesulfonyl-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-methanone;

((S)-3-Ethoxy-pyrrolidin-1-yl)-(4-{4-[4-(4-methanesulfonyl-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-methanone;

Cyano-acetic acid (1R,3S)-3-(4-{4-[4-(2-cyano-acetyl)-piperazin-1-yl]-indol-1-yl}-pyrimidin-2-ylamino)-cyclohexyl ester;

3-(4-{1-[2-((1S,3S)-3-Hydroxy-cyclohexylamino)-pyrimidin-4-yl]-1*H*-indol-4-yl}-piperazin-1-yl)-3-oxo-propionitrile;

3-(4-{1-[2-((1S,3R)-3-Hydroxy-cyclohexylamino)-pyrimidin-4-yl]-1*H*-indol-4-yl}-piperazin-1-yl)-3-oxo-propionitrile;

Cyano-acetic acid (1S,3S)-3-(4-{4-[4-(2-cyano-acetyl)-piperazin-1-yl]-indol-1-yl}-pyrimidin-2-ylamino)-cyclohexyl ester;

1-{4-[1-(2-Cyclohexylamino-pyrimidin-4-yl)-1*H*-indol-4-yl]-piperazin-1-yl}-ethanone;

3-{4-[1-(2-Cyclohexylamino-pyrimidin-4-yl)-1*H*-indol-4-yl]-piperazin-1-yl}-3-oxo-propionitrile;

1-[4-(1-{2-[4-(2-Methoxy-ethoxy)-cyclohexylamino]-pyrimidin-4-yl}-1*H*-indol-4-yl)-piperazin-1-yl]-ethanone;

3-[4-(1-{2-[4-(2-Methoxy-ethoxy)-cyclohexylamino]-pyrimidin-4-yl}-1*H*-indol-4-yl)-piperazin-1-yl]-3-oxo-propionitrile;

1-(4-{1-[2-(4-Methanesulfonylmethyl-cyclohexylamino)-pyrimidin-4-yl]-1*H*-indol-4-yl}-piperazin-1-yl)-ethanone;

3-(4-{1-[2-(4-Methanesulfonylmethyl-cyclohexylamino)-pyrimidin-4-yl]-1*H*-indol-4-yl}-piperazin-1-yl)-3-oxo-propionitrile;

1-[4-(1-{2-[4-(1-Hydroxy-1-methyl-ethyl)-cyclohexylamino]-pyrimidin-4-yl}-1*H*-indol-4-yl)-piperazin-1-yl]-ethanone;

N-[4-(4-{4-[4-(2-Cyano-acetyl)-piperazin-1-yl]-indol-1-yl}-pyrimidin-2-ylamino)-cyclohexyl]-*N*-(2-hydroxy-ethyl)-methanesulfonamide;

3-[4-(1-{2-[4-(1-Hydroxy-1-methyl-ethyl)-cyclohexylamino]-pyrimidin-4-yl}-1*H*-indol-4-

yl)-piperazin-1-yl]-3-oxo-propionitrile;

(4-Ethyl-piperazin-1-yl)-(4-{4-[4-(4-methanesulfonyl-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-methanone;

(4-Cyclopropyl-piperazin-1-yl)-(4-{4-[4-(4-methanesulfonyl-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-methanone;

(4-*tert*-Butyl-piperazin-1-yl)-(4-{4-[4-(4-methanesulfonyl-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-methanone;

(4-Cyclobutyl-piperazin-1-yl)-(4-{4-[4-(4-methanesulfonyl-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-methanone;

(4-{4-[4-(4-Methanesulfonyl-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-(octahydro-pyrido[1,2-*a*]pyrazin-2-yl)-methanone;

(4-{4-[4-(4-Methanesulfonyl-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-(3-trifluoromethyl-5,6-dihydro-8*H*-[1,2,4]triazolo[4,3-*a*]pyrazin-7-yl)-methanone;

(Hexahydro-pyrrolo[1,2-*a*]pyrazin-2-yl)-(4-{4-[4-(4-methanesulfonyl-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-methanone;

(5,6-Dihydro-8*H*-[1,2,4]triazolo[4,3-*a*]pyrazin-7-yl)-(4-{4-[4-(4-methanesulfonyl-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-methanone;

(5,6-Dihydro-8*H*-imidazo[1,2-*a*]pyrazin-7-yl)-(4-{4-[4-(4-methanesulfonyl-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-methanone;

3-(4-{1-[2-(4-Hydroxy-cyclohexylamino)-pyrimidin-4-yl]-1*H*-indol-4-yl}-piperazin-1-yl)-3-oxo-propionitrile;

3-[4-(1-{2-[4-(4-Ethyl-piperazine-1-carbonyl)-cyclohexylamino]-pyrimidin-4-yl}-1*H*-indol-4-yl)-piperazin-1-yl]-3-oxo-propionitrile;

3-(4-{1-[2-(4-Hydroxy-cyclohexylamino)-pyrimidin-4-yl]-1*H*-indol-4-yl}-piperazin-1-yl)-3-oxo-propionitrile;

3-(4-{1-[2-((1S,3R)-3-Hydroxy-cyclopentylamino)-pyrimidin-4-yl]-1*H*-indol-4-yl}-piperazin-1-yl)-3-oxo-propionitrile;

3-(4-{1-[2-((1R,3S)-3-Hydroxy-cyclopentylamino)-pyrimidin-4-yl]-1*H*-indol-4-yl}-piperazin-1-yl)-3-oxo-propionitrile;

3-(4-{1-[2-((1S,3S)-3-Hydroxy-cyclopentylamino)-pyrimidin-4-yl]-1*H*-indol-4-yl}-piperazin-1-yl)-3-oxo-propionitrile;

3-(4-{1-[2-((1R,3R)-3-Hydroxy-cyclopentylamino)-pyrimidin-4-yl]-1*H*-indol-4-yl}-piperazin-1-yl)-3-oxo-propionitrile;

4-{4-[4-(4-Methanesulfonyl-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexanol;

4-(4-Acetyl-piperazin-1-yl)-1-[2-(4-hydroxy-cyclohexylamino)-pyrimidin-4-yl]-1*H*-indole-3-carboxylic acid amide;

4-(4-Acetyl-piperazin-1-yl)-1-[2-(4-methanesulfonylmethyl-cyclohexylamino)-pyrimidin-4-yl]-1*H*-indole-3-carboxylic acid amide;

4-{4-[4-(4-Methanesulfonyl-piperidin-1-yl)-indazol-1-yl]-pyrimidin-2-ylamino}-cyclohexanecarboxylic acid ethyl ester; and

4-{4-[4-(4-Methanesulfonyl-piperidin-1-yl)-indazol-1-yl]-pyrimidin-2-ylamino}-cyclohexanol.

14. A method of treating a JNK-mediated disorder in a subject having a JNK-mediated disorder, said method comprising administering to a subject in need thereof a therapeutically effective amount of the compound of any one of claims 1-13.

15. The method of claim 14, wherein the JNK-mediated disorder is characterized by cellular proliferation.

16. The method of claim 14, wherein the JNK-mediated disorder is arthritis.

17. The method of claim 14, wherein the arthritis is rheumatoid arthritis.

18. The method of claim 14, wherein the JNK-mediated disorder is asthma.

19. The method of claim 14, wherein the JNK-mediated disorder is diabetes.

20. The method of claim 14, wherein the JNK-mediated disorder is Alzheimer's disease.

21. The method of claim 14, wherein the JNK-mediated disorder is Parkinson's disease.

22. The method of claim 14, wherein the JNK-mediated disorder is ischemic stroke.

23. The method of claim 14, wherein the JNK-mediated disorder is cancer.

24. The method of claim 14, wherein the cancer is brain cancer.

25. The method of claim 14, wherein the cancer is leukemia.

26. The method of claim 14, wherein the JNK-mediated disorder is kidney disease.

27. A pharmaceutical composition comprising the compound of any one of claims 1-13, admixed with at least one pharmaceutically acceptable carrier, excipient or diluent.

28. A method for treating arthritis comprising co-administering to a patient in need thereof a therapeutically effective amount of an anti-inflammatory compound in combination with the compound of any one of claims 1-13.


29. Use of the compound of any one of claims 1 to 13 in the manufacture of a medicament for the treatment of an inflammatory disorder.

30. Compound according to any one of the claims 1 to 13 for use in the treatment of an inflammatory disorder.

* * * * * * *

Claims:

1. A compound of formula I



I

or a pharmaceutically acceptable salt thereof,

wherein:

Y' is CH or N;

X is CH or N;

each X^1 is independently halogen, lower alkyl, lower alkoxy, lower haloalkyl, or hydroxy;

m is 0, 1, or 2;

X^2 is H, lower alkyl, lower alkoxy, amido, lower haloalkyl, or lower haloalkoxy;

X^3 is lower alkyl, lower alkoxy, or lower haloalkyl;

p is 0 or 1;

each X^4 is independently lower alkyl, lower alkoxy, lower haloalkyl, hydroxy, lower hydroxylalkyl, $OC(=O)Z^2$, or halogen;

X^5 is lower alkyl;

q is 0, 1, or 2;

s is 0, 1 or2;

r is 0 or 1;

Y is H, OH, $C(=O)Z^2$, $C(=O)OZ^2$, OZ^2, $OC(=O)Z^2$, $N(Z^1)C(=O)(Z^2)$, $C(Z^1)_2S(O)_2Z^2$, $N(Z^1)S(O)_2Z^2$, $N(Z^1)S(O)_2N(Z^1)(Z^2)$, $C(Z^1)_2(Z^2)$, or $(C=O)N(Z^1)(Z^2)$;

Z^1 is H or $Z^{1'}$;

$Z^{1'}$ is lower alkyl, optionally substituted with one or more $Z^{1''}$;

each $Z^{1''}$ is independently halogen, hydroxy, lower haloalkyl, dialkylamino or amino;

Z^2 is H or $Z^{2'}$;

$Z^{2'}$ is hydroxy, lower alkyl, lower alkoxy, lower hydroxyalkyl, lower haloalkyl, cycloalkyl, cycloalkyl lower alkyl, heterocycloalkyl, heterocycloalkyl lower alkyl, optionally substituted with one or more $Z^{2''}$;

each $Z^{2''}$ is independently halogen, hydroxy, lower alkyl, cycloalkyl, cyano, lower haloalkyl, amino, carboxylic acid, ester, or lower alkoxy;

R^1 is a bond, C(=O), C(=O)O, $C(=O)CH_2OC(=O)$, $C(=O)CH_2NHC(=O)O$, or $S(=O)_2$;

R^2 is H or $R^{2'}$;

$R^{2'}$ is hydroxy, lower alkyl, $N(R^3)_2$, lower hydroxyalkyl, or lower haloalkyl, optionally substituted with one or more $R^{2''}$;

each $R^{2''}$ is independently cyano, amino, dialkylamino, hydroxy, lower hydroxyalkyl, or lower alkoxy; and

each R^3 is independently H, lower alkyl, lower cycloalkyl, phenyl, lower heterocycloalkyl, or both R^3 together form a heterocyclic ring;

with the proviso that when X is N, X^2 is H, Y' is CH, R^1 is C(=O), R^2 is methyl, r is 1, m is 0, p is 0, q is 0, Y is $N(Z^1)S(O)_2Z^2$, and Z^2 is methyl, then Z^1 is not H or hydroxyethyl.

2. The compound according to claim 1, wherein m is 0, X^2 is H, p is 0, q is 0, r is 0, X is N, Y' is CH, R^1 is C(=O), R^2 is $R^{2'}$, $R^{2'}$ is methylene, and $R^{2''}$ is cyano.

3. The compound according to claim 1, wherein m is 0, p is 0, q is 0, r is 1, X is N, Y' is CH, R^1 is C(=O), R^2 is $R^{2'}$, $R^{2'}$ is methylene, and $R^{2''}$ is cyano.

4. The compound according to claim 1, wherein m is 0, X^2 is H, p is 0, q is 0, r is 1, X is N, Y' is CH, R^1 is C(=O), R^2 is $R^{2'}$, and $R^{2'}$ is methyl.

5. The compound according to claim 1, wherein m is 0, p is 0, q is 0, r is 1, X is CH, Y' is CH, R^1 is $S(=O)_2$, R^2 is $R^{2'}$, and $R^{2'}$ is methyl.

6. The compound according to claim 1, wherein R^1 is C(=O), R^2 is $R^{2'}$, $R^{2'}$ is methylene, and $R^{2''}$ is cyano.

7. The compound according to claim 1, wherein R^1 is $S(=O)_2$, R^2 is $R^{2'}$, and $R^{2'}$ is methyl.

8. A compound selected from the group consisting of:

N-{4-[4-(4-Piperazin-1-yl-indol-1-yl)-pyrimidin-2-ylamino]-cyclohexyl}-methanesulfonamide;

4-[4-(4-Piperidin-1-yl-indol-1-yl)-pyrimidin-2-ylamino]-cyclohexanol;

N-(4-{4-[4-(4-Methanesulfonyl-piperazin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-methanesulfonamide;

N-(4-{4-[4-(4-Hydroxy-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-methanesulfonamide;

N-(4-{4-[4-(4-Acetyl-piperazin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-*N*-methyl-methanesulfonamide;

N-(4-{4-[4-(4-Methanesulfonyl-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-methanesulfonamide;

4-{1-[2-(4-Methanesulfonylamino-cyclohexylamino)-pyrimidin-4-yl]-1*H*-indol-4-yl}-piperazine-1-carboxylic acid amide;

4-{1-[2-(4-Methanesulfonylamino-cyclohexylamino)-pyrimidin-4-yl]-1*H*-indol-4-yl}-piperazine-1-sulfonic acid amide;

N-[4-(4-{4-[4-(2-Cyano-acetyl)-piperazin-1-yl]-indol-1-yl}-pyrimidin-2-ylamino)-cyclohexyl]-methanesulfonamide;

Acetic acid 2-(4-{1-[2-(4-methanesulfonylamino-cyclohexylamino)-pyrimidin-4-yl]-1*H*-indol-4-yl}-piperazin-1-yl)-2-oxo-ethyl ester;

N-[4-(4-{4-[4-(2-Hydroxy-acetyl)-piperazin-1-yl]-indol-1-yl}-pyrimidin-2-ylamino)-cyclohexyl]-methanesulfonamide;

4-{4-[4-(4-Methanesulfonyl-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexanol;

N-(4-{4-[4-(4-Methanesulfonyl-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-acetamide;

2-(4-{4-[4-(4-Methanesulfonyl-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-propan-2-ol;

[4-{4-[4-(4-Methanesulfonyl-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl] aminodimethylsulfonamide;

4-{4-[4-(4-Methanesulfonyl-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-1-methyl-cyclohexanol;

4-{4-[4-(4-Methanesulfonyl-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-1-methyl-cyclohexanol;

(4-Hydroxy-piperidin-1-yl)-(4-{4-[4-(4-methanesulfonyl-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-methanone;

4-{4-[4-(4-Methanesulfonyl-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexanecarboxylic acid ethylamide;

4-{4-[4-(4-Methanesulfonyl-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexanecarboxylic acid ethyl ester;

1-[(R)-4-(1-{2-[4-(4-Hydroxy-piperidine-1-carbonyl)-cyclohexylamino]-pyrimidin-4-yl}-1*H*-indol-4-yl)-3-methyl-piperazin-1-yl]-ethanone;

[2-(4-{1-[2-(4-Methanesulfonylamino-cyclohexylamino)-pyrimidin-4-yl]-1*H*-indol-4-yl}-piperazin-1-yl)-2-oxo-ethyl]-carbamic acid *tert*-butyl ester;

N-[4-(4-{4-[4-(2-Dimethylamino-acetyl)-piperazin-1-yl]-indol-1-yl}-pyrimidin-2-ylamino)-cyclohexyl]-methanesulfonamide;

N-[4-(4-{4-[4-(2-Amino-acetyl)-piperazin-1-yl]-indol-1-yl}-pyrimidin-2-ylamino)-cyclohexyl]-methanesulfonamide;

3-[4-(1-{2-[4-((R)-3-Hydroxy-pyrrolidin-1-ylmethyl)-cyclohexylamino]-pyrimidin-4-yl}-1*H*-indol-4-yl)-piperazin-1-yl]-3-oxo-propionitrile;

N-[4-(4-{4-[4-(2-Cyano-acetyl)-piperazin-1-yl]-indol-1-yl}-pyrimidin-2-ylamino)-cyclohexyl]-*N*-(2-dimethylamino-ethyl)-methanesulfonamide;

3-(4-{1-[2-(4-Hydroxymethyl-cyclohexylamino)-pyrimidin-4-yl]-1*H*-indol-4-yl}-piperazin-1-yl)-3-oxo-propionitrile;

3-[4-(1-{2-[4-((S)-3-Hydroxy-pyrrolidin-1-ylmethyl)-cyclohexylamino]-pyrimidin-4-yl}-1*H*-indol-4-yl)-piperazin-1-yl]-3-oxo-propionitrile;

1-[4-(1-{2-[4-((R)-3-Hydroxy-pyrrolidin-1-ylmethyl)-cyclohexylamino]-pyrimidin-4-yl}-1*H*-indol-4-yl)-piperazin-1-yl]-ethanone;

(4-Ethoxy-piperidin-1-yl)-(4-{4-[4-(4-methanesulfonyl-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-methanone;

((R)-3-Ethoxy-pyrrolidin-1-yl)-(4-{4-[4-(4-methanesulfonyl-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-methanone;

((S)-3-Ethoxy-pyrrolidin-1-yl)-(4-{4-[4-(4-methanesulfonyl-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-methanone;

Cyano-acetic acid (1R,3S)-3-(4-{4-[4-(2-cyano-acetyl)-piperazin-1-yl]-indol-1-yl}-pyrimidin-2-ylamino)-cyclohexyl ester;

3-(4-{1-[2-((1S,3S)-3-Hydroxy-cyclohexylamino)-pyrimidin-4-yl]-1*H*-indol-4-yl}-piperazin-1-yl)-3-oxo-propionitrile;

3-(4-{1-[2-((1S,3R)-3-Hydroxy-cyclohexylamino)-pyrimidin-4-yl]-1*H*-indol-4-yl}-piperazin-1-yl)-3-oxo-propionitrile;

Cyano-acetic acid (1S,3S)-3-(4-{4-[4-(2-cyano-acetyl)-piperazin-1-yl]-indol-1-yl}-pyrimidin-2-ylamino)-cyclohexyl ester;

1-{4-[1-(2-Cyclohexylamino-pyrimidin-4-yl)-1*H*-indol-4-yl]-piperazin-1-yl}-ethanone;

3-{4-[1-(2-Cyclohexylamino-pyrimidin-4-yl)-1*H*-indol-4-yl]-piperazin-1-yl}-3-oxo-propionitrile;

1-[4-(1-{2-[4-(2-Methoxy-ethoxy)-cyclohexylamino]-pyrimidin-4-yl}-1*H*-indol-4-yl)-piperazin-1-yl]-ethanone;

3-[4-(1-{2-[4-(2-Methoxy-ethoxy)-cyclohexylamino]-pyrimidin-4-yl}-1*H*-indol-4-yl)-piperazin-1-yl]-3-oxo-propionitrile;

1-(4-{1-[2-(4-Methanesulfonylmethyl-cyclohexylamino)-pyrimidin-4-yl]-1*H*-indol-4-yl}-piperazin-1-yl)-ethanone;

3-(4-{1-[2-(4-Methanesulfonylmethyl-cyclohexylamino)-pyrimidin-4-yl]-1*H*-indol-4-yl}-piperazin-1-yl)-3-oxo-propionitrile;

1-[4-(1-{2-[4-(1-Hydroxy-1-methyl-ethyl)-cyclohexylamino]-pyrimidin-4-yl}-1*H*-indol-4-yl)-piperazin-1-yl]-ethanone;

N-[4-(4-{4-[4-(2-Cyano-acetyl)-piperazin-1-yl]-indol-1-yl}-pyrimidin-2-ylamino)-cyclohexyl]-*N*-(2-hydroxy-ethyl)-methanesulfonamide;

3-[4-(1-{2-[4-(1-Hydroxy-1-methyl-ethyl)-cyclohexylamino]-pyrimidin-4-yl}-1*H*-indol-4-yl)-piperazin-1-yl]-3-oxo-propionitrile;

(4-Ethyl-piperazin-1-yl)-(4-{4-[4-(4-methanesulfonyl-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-methanone;

(4-Cyclopropyl-piperazin-1-yl)-(4-{4-[4-(4-methanesulfonyl-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-methanone;

(4-*tert*-Butyl-piperazin-1-yl)-(4-{4-[4-(4-methanesulfonyl-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-methanone;

(4-Cyclobutyl-piperazin-1-yl)-(4-{4-[4-(4-methanesulfonyl-piperidin-1-yl)-indol-1-yl]-

pyrimidin-2-ylamino}-cyclohexyl)-methanone;

(4-{4-[4-(4-Methanesulfonyl-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-(octahydro-pyrido[1,2-*a*]pyrazin-2-yl)-methanone;

(4-{4-[4-(4-Methanesulfonyl-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-(3-trifluoromethyl-5,6-dihydro-8*H*-[1,2,4]triazolo[4,3-*a*]pyrazin-7-yl)-methanone;

(Hexahydro-pyrrolo[1,2-*a*]pyrazin-2-yl)-(4-{4-[4-(4-methanesulfonyl-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-methanone;

(5,6-Dihydro-8*H*-[1,2,4]triazolo[4,3-*a*]pyrazin-7-yl)-(4-{4-[4-(4-methanesulfonyl-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-methanone;

(5,6-Dihydro-8*H*-imidazo[1,2-*a*]pyrazin-7-yl)-(4-{4-[4-(4-methanesulfonyl-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexyl)-methanone;

3-(4-{1-[2-(4-Hydroxy-cyclohexylamino)-pyrimidin-4-yl]-1*H*-indol-4-yl}-piperazin-1-yl)-3-oxo-propionitrile;

3-[4-(1-{2-[4-(4-Ethyl-piperazine-1-carbonyl)-cyclohexylamino]-pyrimidin-4-yl}-1*H*-indol-4-yl)-piperazin-1-yl]-3-oxo-propionitrile;

3-(4-{1-[2-(4-Hydroxy-cyclohexylamino)-pyrimidin-4-yl]-1*H*-indol-4-yl}-piperazin-1-yl)-3-oxo-propionitrile;

3-(4-{1-[2-((1S,3R)-3-Hydroxy-cyclopentylamino)-pyrimidin-4-yl]-1*H*-indol-4-yl}-piperazin-1-yl)-3-oxo-propionitrile;

3-(4-{1-[2-((1R,3S)-3-Hydroxy-cyclopentylamino)-pyrimidin-4-yl]-1*H*-indol-4-yl}-piperazin-1-yl)-3-oxo-propionitrile;

3-(4-{1-[2-((1S,3S)-3-Hydroxy-cyclopentylamino)-pyrimidin-4-yl]-1*H*-indol-4-yl}-piperazin-1-yl)-3-oxo-propionitrile;

3-(4-{1-[2-((1R,3R)-3-Hydroxy-cyclopentylamino)-pyrimidin-4-yl]-1*H*-indol-4-yl}-piperazin-1-yl)-3-oxo-propionitrile;

4-{4-[4-(4-Methanesulfonyl-piperidin-1-yl)-indol-1-yl]-pyrimidin-2-ylamino}-cyclohexanol;

4-(4-Acetyl-piperazin-1-yl)-1-[2-(4-hydroxy-cyclohexylamino)-pyrimidin-4-yl]-1*H*-indole-3-carboxylic acid amide;

4-(4-Acetyl-piperazin-1-yl)-1-[2-(4-methanesulfonylmethyl-cyclohexylamino)-pyrimidin-4-yl]-1*H*-indole-3-carboxylic acid amide;

4-{4-[4-(4-Methanesulfonyl-piperidin-1-yl)-indazol-1-yl]-pyrimidin-2-ylamino}-cyclohexanecarboxylic acid ethyl ester; and

4-{4-[4-(4-Methanesulfonyl-piperidin-1-yl)-indazol-1-yl]-pyrimidin-2-ylamino}-cyclohexanol.